This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

GS-938

Gilead Sciences, Inc.

Drug Names(s): PSI-352938, PSI-938, GS-0938

Description: PSI-938 is a third generation prodrug purine (guanosine) nucleotide analogue polymerase inhibitor of hepatitis C virus (HCV).

Deal Structure: In November 2011, Gilead and Pharmasset announced that the companies have signed a definitive agreement under which Gilead will acquire Pharmasset for $137 per share in cash. The transaction values Pharmasset at approximately $11 billion. In January 2012, Gilead announced the successful completion of the tender offer for all of the outstanding shares of common stock of Pharmasset.


GS-938 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug